Literature DB >> 8202506

A role for destabilizing amino acid replacements in light-chain amyloidosis.

M R Hurle1, L R Helms, L Li, W Chan, R Wetzel.   

Abstract

Light-chain (L-chain) amyloidosis is characterized by deposition of fibrillar aggregates composed of the N-terminal L-chain variable region (VL) domain of an immunoglobulin, generally in individuals overproducing a monoclonal L chain. In addition to proteolytic fragmentation and high protein concentration, particular amino acid substitutions may also contribute to the tendency of an L chain to aggregate in L-chain amyloidosis, although evidence in support of this has been limited and difficult to interpret. In this paper we identify particular amino acid replacements at specific positions in the VL domain that are occupied at frequencies significantly higher in those L chains associated with amyloidosis. Analysis of the structural model for the VL domain of the Bence-Jones protein REI suggests that these positions play important roles in maintaining domain structure and stability. Using an Escherichia coli expression system, we prepared single-point mutants of REI VL incorporating amyloid-associated amino acid replacements that are both rare and located at structurally important positions. These mutants support ordered aggregate formation in an in vitro L-chain fibril formation model in which wild-type REI VL remains soluble. Moreover, the ability of these sequences to aggregate in vitro correlates well with the extent to which domain stability is decreased in denaturant-induced unfolding. The results are consistent with a mechanism for the disease process in which the VL domain, either before or after proteolytic cleavage from the L-chain constant region domain, unfolds by virtue of one or more destabilizing amino acid replacements to generate an aggregation-prone nonnative state.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8202506      PMCID: PMC44012          DOI: 10.1073/pnas.91.12.5446

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  Refined crystal structure of deoxyhemoglobin S. II. Molecular interactions in the crystal.

Authors:  E A Padlan; W E Love
Journal:  J Biol Chem       Date:  1985-07-15       Impact factor: 5.157

2.  Polymorphism in a kappa I primary (AL) amyloid protein (BAN).

Authors:  F E Dwulet; T P O'Connor; M D Benson
Journal:  Mol Immunol       Date:  1986-01       Impact factor: 4.407

3.  Structural studies of a carbohydrate-containing immunoglobulin-lambda-light-chain amyloid-fibril protein (AL) of variable subgroup III.

Authors:  E Holm; K Sletten; G Husby
Journal:  Biochem J       Date:  1986-11-01       Impact factor: 3.857

4.  Creation of "amyloid" fibrils from Bence Jones proteins in vitro.

Authors:  G G Glenner; D Ein; E D Eanes; H A Bladen; W Terry; D L Page
Journal:  Science       Date:  1971-11-12       Impact factor: 47.728

5.  Primary structure of the variable region of an amyloidogenic Bence Jones protein NIG-77.

Authors:  H Tonoike; F Kametani; A Hoshi; T Shinoda; T Isobe
Journal:  Biochem Biophys Res Commun       Date:  1985-02-15       Impact factor: 3.575

6.  Amyloid production in human myeloma stem-cell culture, with morphologic evidence of amyloid secretion by associated macrophages.

Authors:  B G Durie; B Persky; B J Soehnlen; T M Grogan; S E Salmon
Journal:  N Engl J Med       Date:  1982-12-30       Impact factor: 91.245

Review 7.  An update of clinical, pathologic, and biochemical aspects of amyloidosis.

Authors:  A S Cohen
Journal:  Int J Dermatol       Date:  1981-10       Impact factor: 2.736

8.  Amino acid sequence of a lambda VI primary (AL) amyloid protein (WLT).

Authors:  F E Dwulet; K Strako; M D Benson
Journal:  Scand J Immunol       Date:  1985-12       Impact factor: 3.487

9.  Is the formation of AL-type amyloid promoted by structural peculiarities of immunoglobulin L-chains? Primary structure of an amyloidogenic lambda-L-chain (BJP-ZIM).

Authors:  M Eulitz; M Breuer; R P Linke
Journal:  Biol Chem Hoppe Seyler       Date:  1987-07

10.  Pathogenic potential of human monoclonal immunoglobulin light chains: relationship of in vitro aggregation to in vivo organ deposition.

Authors:  E A Myatt; F A Westholm; D T Weiss; A Solomon; M Schiffer; F J Stevens
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

View more
  89 in total

1.  Somatic mutations of the L12a gene in V-kappa(1) light chain deposition disease: potential effects on aberrant protein conformation and deposition.

Authors:  R Vidal; F Goñi; F Stevens; P Aucouturier; A Kumar; B Frangione; J Ghiso; G Gallo
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

2.  Physicochemical consequences of amino acid variations that contribute to fibril formation by immunoglobulin light chains.

Authors:  R Raffen; L J Dieckman; M Szpunar; C Wunschl; P R Pokkuluri; P Dave; P Wilkins Stevens; X Cai; M Schiffer; F J Stevens
Journal:  Protein Sci       Date:  1999-03       Impact factor: 6.725

3.  Protein engineering as a strategy to avoid formation of amyloid fibrils.

Authors:  V Villegas; J Zurdo; V V Filimonov; F X Avilés; C M Dobson; L Serrano
Journal:  Protein Sci       Date:  2000-09       Impact factor: 6.725

4.  A systematic exploration of the influence of the protein stability on amyloid fibril formation in vitro.

Authors:  M Ramirez-Alvarado; J S Merkel; L Regan
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

5.  The solution structure of human beta2-microglobulin reveals the prodromes of its amyloid transition.

Authors:  Giuliana Verdone; Alessandra Corazza; Paolo Viglino; Fabio Pettirossi; Sofia Giorgetti; Palma Mangione; Alessia Andreola; Monica Stoppini; Vittorio Bellotti; Gennaro Esposito
Journal:  Protein Sci       Date:  2002-03       Impact factor: 6.725

6.  Mutations in the B1 domain of protein G that delay the onset of amyloid fibril formation in vitro.

Authors:  Marina Ramírez-Alvarado; Melanie J Cocco; Lynne Regan
Journal:  Protein Sci       Date:  2003-03       Impact factor: 6.725

Review 7.  Protein aggregation in disease: a role for folding intermediates forming specific multimeric interactions.

Authors:  Arthur Horwich
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

8.  The fibril_one on-line database: mutations, experimental conditions, and trends associated with amyloid fibril formation.

Authors:  Jennifer A Siepen; David R Westhead
Journal:  Protein Sci       Date:  2002-07       Impact factor: 6.725

9.  Amyloid-forming peptides selected proteolytically from phage display library.

Authors:  Katarzyna Koscielska-Kasprzak; Jacek Otlewski
Journal:  Protein Sci       Date:  2003-08       Impact factor: 6.725

10.  Analysis of somatic hypermutation and antigenic selection in the clonal B cell in immunoglobulin light chain amyloidosis (AL).

Authors:  Roshini S Abraham; Susan M Geyer; Marina Ramírez-Alvarado; Tammy L Price-Troska; Morie A Gertz; Rafael Fonseca
Journal:  J Clin Immunol       Date:  2004-07       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.